[A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):]

Gan to kagaku ryoho. Cancer & chemotherapy

Volumn 33, Issue , 2006, Pages 138-143

  Oki, Eiji ^a   Kakeji, Yoshihiro ^a   Yoshida, Rintaro ^a   Ikeda, Keisuke ^a   Nishida, Kojiro ^a   Koga, Tadashi ^a   Egashira, Akinori ^a   Tokunaga, Eriko ^a   Morita, Masaru ^a   Baba, Hideo ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR; URACIL;

ADJUVANT CHEMOTHERAPY; BIOASSAY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; LYMPH NODE DISSECTION; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTAL NEOPLASMS; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ENDPOINT DETERMINATION; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 84925554298     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)